Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Psoriasis × Etanercept × Clear all

Phase

Phase 3 3 Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 2 Psoriasis 1 Pancreatic Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Lymphoma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1 Diabetes Mellitus, Type 1 1 Cytokine Release Syndrome 1 Adenocarcinoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00585650 2023-08-18

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

University of California, Irvine

Phase 1/2 Completed

20 enrolled 5 charts

Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡